Built on a foundation of interactive video and audio patient data
Accurate confirmation of medication ingestion
Validated against plasma blood levels
20% - 60% improvements according to blood levels
Rich data fuels predictive insights
Over 1 Million behavioral interactions with IMA
In drug development, we are defining new methodologies and enrichment strategies
Clear value is essential in understanding the application of new technology. AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials. AiCure is also demonstrating significant results by introducing new trial methodologies such as placebo lead-in periods, micro-reimbursements, and other approaches directly correlated with patient engagement and clinical endpoints.
For payors, we are reducing medical costs and waste
Medication adherence is one of the few parameters in healthcare that is directly linked to medical costs. AiCure has demonstrated significant savings for some of the largest payors and states by ensuring high-risk patient populations stay on therapy.
For science and the healthcare industry, we are developing novel clinical endpoints through computational diagnostics
AiCure is pioneering a new set of tools to help researchers and clinicians understand and predict how patients respond to treatment. Advances in artificial intelligence allow computers to capture physiological datapoints that characterize expressivity, psychomotor function, and cognition. Whether a patient has schizophrenia or congestive heart failure, the degree to which they are able to adhere and respond to treatment depends in great part on their mood, their ability to move and to concentrate. AiCure is leading a multi-stakeholder R&D effort with industry and academia to develop these transdiagnostic domains and novel sensitive endpoints.
5 Q’s for Adam Hanina, CEO of AiCure
The Center for Data Innovation spoke with Adam Hanina, chief executive officer of AiCure, a healthcare software company based in…
AiCure Named to the 2018 AI 100, Highlighting Advancements in Artificial Intelligence for Patient Monitoring
SAN FRANCISCO, Dec. 12, 2017 /PRNewswire/ — CB Insights today named AiCure to the prestigious …
AiCure's Series B Expands Core AI Clinical Research AND Population Health Services
NEW YORK, November 17, 2017 – AiCure, a clinically-validated patient monitoring platform that uses artificial intelligence today announced the completion…
Stroke patients use artificial intelligence to ensure full therapeutic benefit
Study Highlights Blood tests showed that 100% of patients in the artificial intelligence intervention arm received full therapeutic benefit, compared…
AiCure wins Best Technological Development in Clinical Trials Award – Patient-focused at The 12th Annual Scrip Awards.
The Scrip Awards acknowledge and commend the pharmaceutical sector’s stand-out performers across all areas of the…
Intellectual property - Over 100 patents filed